A study assessing the levels of ADAM10 in the platelets and cerebral spinal fluid of AD patients found that the ADAM10 levels are reduced as compared to non-AD controls (Colciaghi et al., 2002, 2004; Sogorb-Esteve et al., 2018). The gene discussed is ADAM10; the disease is Alzheimer disease.